0001209191-21-056041.txt : 20210914
0001209191-21-056041.hdr.sgml : 20210914
20210914192050
ACCESSION NUMBER: 0001209191-21-056041
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210914
FILED AS OF DATE: 20210914
DATE AS OF CHANGE: 20210914
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Demetri George
CENTRAL INDEX KEY: 0001639147
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38550
FILM NUMBER: 211253738
MAIL ADDRESS:
STREET 1: BLUEPRINT MEDICINES CORP.
STREET 2: 215 FIRST STREET, SUITE 340/350
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Translate Bio, Inc.
CENTRAL INDEX KEY: 0001693415
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 611807780
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 29 HARTWELL AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 617-945-7361
MAIL ADDRESS:
STREET 1: 29 HARTWELL AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
FORMER COMPANY:
FORMER CONFORMED NAME: RaNA Therapeutics, Inc.
DATE OF NAME CHANGE: 20161228
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-09-14
0
0001693415
Translate Bio, Inc.
TBIO
0001639147
Demetri George
C/O TRANSLATE BIO, INC.
29 HARTWELL AVE
LEXINGTON
MA
02421
1
0
0
0
Stock Option (right to buy)
10.15
2021-09-14
4
S
0
37800
0.00
D
2029-07-11
Common Stock
37800
0
D
Stock Option (right to buy)
15.33
2021-09-14
4
S
0
18900
0.00
D
2030-06-15
Common Stock
18900
0
D
Stock Option (right to buy)
20.43
2021-09-14
4
S
0
20000
0.00
D
2031-06-15
Common Stock
20000
0
D
As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021. Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share.
The shares underlying this option are scheduled to vest and become exercisable in equal monthly installments, beginning on August 12, 2019 and ending on the three year anniversary of July 12, 2019.
This option was granted on June 16, 2020. The shares underlying this option became fully vested on the date of the Issuer's annual meeting of stockholders following the date of the grant, or June 16, 2021.
This option was granted on June 16, 2021. This option will vest and become exercisable in full on the one year anniversary of the date of the award, or if earlier, the date of the Issuer's next annual meeting of stockholders following the date of the grant.
/s/ Paul D. Burgess, as attorney-in-fact for George Demetri, MD
2021-09-14